Evotec acquires 100% of the capital of Rigenerand

May 30, 2022 - Xyence Capital SGR S.p.A. sells its stake (50.2%) in the share capital of Rigenerand S.r.l. - a leading Italian company in the research and development of advanced cancer therapies - to Evotec SE, a listed German group specialized in the research and development of innovative therapies.

Xyence Capital has been in Rigenerand's share capital since 2016 and has contributed to the creation of a 1,200-square-meter facility consisting of a Cell Factory BL2 / BL3 (Biosafety Level 2 and Biosafety Level 3), research and development laboratories, quality control facilities, offices, and warehouses - making the company highly attractive for a cell therapy international player like Evotec.

The transaction is part of the broader framework for the revitalization of the Mirandola Biomedical District, Italy's main industrial district specialized in biomedical engineering and medical device manufacturing located in the Mirandola area and in neighboring towns such as Medolla.